BTIG analyst Ryan Zimmerman maintained a Buy rating on Integra Lifesciences (NASDAQ:IART) Holdings Corp. on Thursday, setting a price target of $72, which is approximately 1.19% above the present share price of $71.15.
Zimmerman expects Integra Lifesciences Holdings Corp. to post earnings per share (EPS) of $0.38 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Integra Lifesciences, with an average price target of $70.29.
The analysts price targets range from a high of $80 to a low of $60.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $370.23 million and a net profit of $57.54 million. The company's market cap is $6 billion.
According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 35.8% and a 70.34% success rate.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.